To determine the combined growth inhibitory effect of selumetinib (MEK inhibitor) and KRT-232 (MDM2 inhibitor), we performed sulforhodamine B (SRB) assay in KRAS-mutated CRC cell lines HCT116 (KRAS G13D), LoVo (KRAS G13D), and B1011CL (KRAS A148T) and BRAF-mutated PTC cell line MDA-PDX.008CL (PDX.008CL, BRAF K601N). The gene discussed is MDM2; the disease is colorectal carcinoma.